Updated:
Leica Biosystems
Leica Biosystems, a Danaher company and a global leader in anatomic pathology, provides integrated workflow solutions from biopsy to AI diagnostics since...
Leica Biosystems
Leica Biosystems was founded in 1872, starting with microtome technology from R. Jung GMBH. The firm is now a Danaher company, headquartered in St. Louis, and focused exclusively on cancer diagnostics — from biopsy to diagnosis. The firm's strategy spans four interconnected segments: histology solutions (tissue processors, microtomes, slide stainers), IHC & ISH (automated staining instruments and reagents), digital pathology (Aperio scanners and management software), and AI-powered diagnostics (Aperio AI Store, partnerships with Mindpeak and AstraZeneca). Confirmed deals include a global reseller agreement with Mindpeak in 2026 and a collaboration with AstraZeneca and Daiichi Sankyo to develop AI diagnostics for NSCLC. Geographic reach is global, with over 3,000 experts positioned across North America, Europe, and Asia. The firm employs over 3,000 professionals worldwide and is structured as an operating company within Danaher. Recent activity includes the May 2026 announcement of an expanded collaboration with AstraZeneca and Daiichi Sankyo to develop an end-to-end system for TROP2 quantitative diagnostics in non-small cell lung cancer (per firm press release, May 2026). Leica Biosystems' distinct structural advantage lies in its Danaher affiliation — providing capital, R&D scale, and regulatory infrastructure — while operating as a dedicated cancer diagnostics platform. This allows the firm to offer a fully integrated workflow from biopsy to digital AI diagnostics, a model few competitors match.
General information
Firm type
Asset Manager
Year founded
1872
AUM
Undisclosed
Location
Region
North America
Country
United States
City
St. Louis
Corporate office
St. Louis, MO, United States
Principals
Koichi Ohshima
Professor, Department of Pathology, Kurume University
Sylvia L. Asa
Consultant in Endocrine Pathology, University Hospitals Cleveland Medical Center
Sector focus
Frequently asked questions
What is the commercial relationship between Leica Biosystems and Danaher?
Leica Biosystems operates as a Danaher operating company. Since being acquired by Danaher (now part of a larger science and technology conglomerate), Leica Biosystems benefits from Danaher's capital, R&D infrastructure, and regulatory expertise, which allows it to scale its pathology workflow solutions globally.
What investment stages and asset classes does Leica Biosystems target?
Leica Biosystems does not act as an external investor; it is a Danaher operating company that develops, manufactures, and sells anatomic pathology products and diagnostics. Its focus is on developing instruments, consumables, software, and AI tools for cancer diagnostics.
How does Leica Biosystems source and develop its AI pathology tools?
Leica Biosystems develops some AI tools internally and partners with third-party developers through its Aperio AI Store. In 2026, the firm signed a global reseller agreement with Mindpeak to expand access to AI pathology solutions. The firm also collaborates with pharmaceutical companies like AstraZeneca and Daiichi Sankyo to develop AI-powered companion diagnostics.
What is the geographic footprint of Leica Biosystems?
The firm has a global presence with over 3,000 experts worldwide. Headquarters are in St. Louis, USA, with significant operations in Europe (Newcastle, UK) and Asia. Reference customers include institutions in Japan (Kurume University) and the United States (University Hospitals Cleveland Medical Center).
Does Leica Biosystems participate in external fund commitments or direct investments?
No. Leica Biosystems is a Danaher operating company focused on developing and selling pathology equipment, consumables, and digital solutions. It does not function as an investment entity or asset manager.
How is Leica Biosystems related to the Mindpeak reseller agreement announced in 2026?
Leica Biosystems and Mindpeak entered a global reseller agreement in 2026, allowing Leica to distribute Mindpeak's AI pathology software through its Aperio AI Store platform. This expands the AI tools available to Leica's customers within a single interface.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: